Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liu, Yan Qing ^a   Yuan, Ling Min ^a   Gao, Zhang Zhao ^a   Xiao, Yong Sheng ^a   Sun, Hong Ying ^a   Yu, Lu Shan ^a   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; ISOENZYME; QUERCETIN; UDP-GLUCURONOSYLTRANSFERASE 1A9; UGT1A1 ENZYME;

ANIMAL; CHEMISTRY; ENZYME SPECIFICITY; GLYCOSYLATION; HUMAN; KINETICS; PROTEIN MULTIMERIZATION; SF9 CELL LINE; SPODOPTERA;

ANIMALS; GLUCURONOSYLTRANSFERASE; GLYCOSYLATION; HUMANS; ISOENZYMES; KINETICS; PROTEIN MULTIMERIZATION; QUERCETIN; SF9 CELLS; SPODOPTERA; SUBSTRATE SPECIFICITY;

EID: 84962428127     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23763     Document Type: Article

References (38)

1. Oda, S., Fukami, T., Yokoi, T. & Nakajima, M. A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab. Pharmacok. 30, 30-51 (2015).
2. Wen, Z., Tallman, M. N., Ali, S. Y. & Smith, P. C. UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab. Dispos. 35, 371-380 (2007).
3. Tukey, R. H., Strassburg, C. P. & Mackenzie, P. I. Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 62, 446-450 (2002).
4. Bernard, O. & Guillemette, C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos. 32, 775-778 (2004).
5. Harding, D., Jeremiah Sj Fau-Povey, S., Povey S Fau-Burchell, B. & Burchell, B. Chromosomal mapping of a human phenol UDPglucuronosyltransferase, GNT1. Ann. Hum. Genet. 54, 17-21 (1990).
6. Bosma, P. J. et al. Mechanisms of inherited deficiencies of multiple UDP-glucuronosyltransferase isoforms in two patients with Crigler-Najjar syndrome, type I. FASEB J. 6, 2859-2863 (1992).
7. Vogel, A. et al. Polymorphisms of the carcinogen detoxifying UDP-glucuronosyltransferase UGT1A7 in proximal digestive tract cancer. Z. Gastroenterol. 40, 497-502 (2002).
8. Burchell, B. Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation. Am. J. Pharmacogenomics 3, 37-52 (2003).
9. Chu, X. M. et al. Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur. J. Clin. Pharmacol. 68, 1395-1401 (2012).
10. Lévesque, E., Girard, H., Journault, K., Lépine, J. & G., C. Regulation of the UGT1A1 bilirubin-conjugating pathway: role of a new splicing event at the UGT1A locus. Hepatology 45, 128-138 (2007).
11. Wang, H., Yuan, L. & Zeng, S. Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochem. Pharmacol. 82, 1757-1763 (2011).
12. Villeneuve, L., Girard, H., Fortier, L. C., Gagné, J. F. & G., C. Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10- hydroxycamptothecin and Flavopiridol Anticancer Drugs. J. Pharmacol. Exp. Ther. 307, 117-128 (2003).
13. Jinno, H. et al. Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients. J. Pharmacol. Exp. Ther. 306, 688-693 (2003).
14. Olson, K. C. et al. Functional Characterization of Low-Prevalence Missense Polymorphisms in the UDP-Glucuronosyltransferase 1A9 Gene. Drug Metab. Dispos. 37, 1999-2007 (2009).
15. Chen, Y. K., Chen, S., Li, X. & Zeng, S. Quantitative regioselectivity of glucuronidation of quercetin by recombinant UDPglucuronosyltransferases 1A9 and 1A3 using enzymatic kinetic parameters. Xenobiotica 35, 943-954 (2005).
16. Chen, Y. K., Chen, S. Q., Li, X., Wang, X. & Zeng, S. Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population. Drug Metab. Dispos. 34, 1462-1467 (2006).
17. Ghosh, S. S. et al. Homodimerization of human bilirubin-uridine-diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) and its functional implications. J. Biol. Chem. 276, 42108-42115 (2001).
18. Kurkela, M. et al. Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J. Biol. Chem. 278, 3536-3544 (2003).
19. Operaña, T. N. & Tukey, R. H. Oligomerization of the UDP-glucuronosyltransferase 1A proteins: homo- and heterodimerization analysis by fluorescence resonance energy transfer and co-immunoprecipitation. J. Biol. Chem. 282, 4821-4829 (2007).
20. Fujiwara, R. et al. Effects of Coexpression of UGT1A9 on Enzymatic Activities of Human UGT1A Isoforms. Drug Metab.d Dispos. 35, 747-757 (2007).
21. Fujiwara, R., Nakajima, M., Yamanaka, H., Katoh, M. & Y., T. Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. Drug Metab.d Dispos. 35, 1781-1787 (2007).
22. Zhang, X., Meng, X., Wang, Y., Yan, W. & Yang, J. Comprehensive Analysis of UGT1A1 Genetic Polymorphisms in Chinese Tibetan and Han Populations. Biochem. Genet. 50, 967-977 (2012).
23. Sai, K. et al. UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecanadministered Japanese Patients with Cancer. Clin. Pharmacol. Ther. 75, 501-515 (2004).
24. Saito, Y. et al. Close Association of UGT1A9 IVS1 + 399C > T with UGT1A1∗28,∗6, or∗60 Haplotype and Its Apparent Influence on 7-Ethyl-10-hydroxycamptothecin (SN-38) Glucuronidation in Japanese. Drug Metab.d Dispos. 37, 272-276 (2009).
25. Reif, M. M. & Oostenbrink, C. Molecular dynamics simulation of configurational ensembles compatible with experimental FRET efficiency data through a restraint on instantaneous FRET efficiencies. J. Comp. Chem. 35, 2319-2332 (2014).
26. dos Remedios, C. G. & Moens, P. D. Fluorescence resonance energy transfer spectroscopy is a reliable "ruler" for measuring structural changes in proteins. Dispelling the problem of the unknown orientation factor. J. Struct. Biol. 115, 175-185 (1995).
27. Lerner, E., Orevi, T., Ben Ishay, E., Amir, D. & Haas, E. Kinetics of fast changing intramolecular distance distributions obtained by combined analysis of FRET efficiency kinetics and time-resolved FRET equilibrium measurements. Biophys. J. 106, 667-676 (2014).
28. Jayasundar, J. J., Xing, J., Robinson, J. M., Cheung, H. C. & Dong, W. J. Molecular dynamics simulations of the cardiac troponin complex performed with FRET distances as restraints. PloS one 9, e87135 (2014).
29. Wang, L., Wang, Y. & Ragauskas, A. J. Determination of cellulase colocalization on cellulose fiber with quantitative FRET measured by acceptor photobleaching and spectrally unmixing fluorescence microscopy. Analyst 137, 1319-1324 (2012).
30. Smolin, N. & Robia, S. L. A structural mechanism for calcium transporter headpiece closure. J. Phys. chem. B 119, 1407-1415 (2015).
31. Bellemare, J. et al. Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drugmetabolizing tissues in humans. J. Pathol. 223, 425-435 (2011).
32. Fujiwara, R. et al. Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. J. Pharm. Sci. 99, 442-454 (2010).
33. Yuan, L., Qian, S., Xiao, Y., Sun, H. & Z., S. Homo- and hetero-dimerization of human UDP-glucuronosyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity. Biochem. Pharmacol. 95, 58-70 (2015).
34. Laakkonen, L. & Finel, M. A Molecular Model of the Human UDP-Glucuronosyltransferase 1A1, Its Membrane Orientation, and the Interactions between Different Parts of the Enzyme. Mol. Pharmacol. 77, 931-939 (2010).
35. Korprasertthaworn, P. et al. Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity. Biochem. Pharmacol. 84, 1511-1521 (2012).
36. Nagar, S. & Remmel, R. P. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25, 1659-1672 (2000).
37. Food and Drug Administration (FDA), Guidance for Industry-Bioanalytical Method Validation, 2013.09.
38. Houston, J. B. & Kenworthy, K. E. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos. 28, 246-254 (2000).